RGNT (Regentis Biomaterials) Debt-to-Asset : 0.16 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $2.00
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials Debt-to-Asset?

Regentis Biomaterials RGNT -2.91% 14 Debt-to-Asset is 0.16 as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Regentis Biomaterials's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $1.20 Mil. Regentis Biomaterials's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.00 Mil. Regentis Biomaterials's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $7.62 Mil. Regentis Biomaterials's debt to asset for the quarter that ended in Dec. 2025 was 0.16.

Regentis Biomaterials  (AMEX:RGNT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Regentis Biomaterials Debt-to-Asset Related Terms

Regentis Biomaterials Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials Debt-to-Asset Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 1.95 3.77 21.15 10.26 0.16

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 21.15 13.65 10.26 17.19 0.16

RGNT vs BNGO, ZJYL, UEEC: Debt-to-Asset Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regentis Biomaterials Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's Debt-to-Asset falls into.


RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Regentis Biomaterials's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.197 + 0) / 7.618
=0.16

Regentis Biomaterials's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.197 + 0) / 7.618
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.16 mean?
Regentis Biomaterials (RGNT) has a Debt-to-Asset of 0.16 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' Debt-to-Asset too high?
Regentis Biomaterials' current Debt-to-Asset is 0.16. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Debt-to-Asset compare to BNGO and ZJYL?
Regentis Biomaterials' Debt-to-Asset of 0.16 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Regentis Biomaterials and its competitors. Regentis Biomaterials's current Debt-to-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Debt-to-Asset of 0.16. The current Debt-to-Asset is 0.16. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Debt-to-Asset is 0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price